StockFacets
About
Sign-up
Sign-in
Earnings Calendar
Prices are updated after-hours
Published
Previous years
93
Publishing Date
2022 - 03 - 15
2
2022 - 03 - 04
2
2022 - 02 - 11
2
2022 - 02 - 10
3
2022 - 01 - 04
2
2021 - 12 - 14
2
2021 - 12 - 13
2
2021 - 12 - 01
2
2021 - 09 - 21
1
2021 - 09 - 20
1
2021 - 09 - 17
1
2021 - 09 - 16
1
2021 - 09 - 13
1
2021 - 09 - 09
1
2021 - 09 - 02
1
2021 - 09 - 01
1
2021 - 08 - 16
1
2021 - 07 - 26
1
2021 - 07 - 23
1
2021 - 07 - 21
1
2021 - 07 - 19
1
2021 - 07 - 14
1
2021 - 07 - 06
1
2021 - 07 - 02
1
2021 - 06 - 23
1
2021 - 06 - 21
2
2021 - 06 - 11
1
2021 - 06 - 04
1
2021 - 06 - 03
1
2021 - 06 - 02
1
2021 - 06 - 01
2
2021 - 05 - 26
1
2021 - 05 - 24
1
2021 - 05 - 19
2
2021 - 05 - 17
1
2021 - 05 - 01
1
2021 - 04 - 20
1
2021 - 04 - 19
1
2021 - 04 - 16
1
2021 - 04 - 13
1
2021 - 04 - 12
1
2021 - 04 - 09
1
2021 - 03 - 25
1
2021 - 03 - 24
1
2021 - 03 - 17
1
2021 - 03 - 04
1
2021 - 03 - 02
1
2021 - 02 - 09
2
2021 - 02 - 02
1
2021 - 01 - 28
1
2021 - 01 - 14
1
2020 - 12 - 22
1
2020 - 12 - 17
1
2020 - 12 - 15
1
2020 - 12 - 08
1
2020 - 12 - 03
1
2020 - 12 - 02
1
2020 - 06 - 23
1
2020 - 01 - 09
1
2018 - 11 - 13
2
Sector
Commercial services
1
Finance
1
Health services
2
Health technology
78
Manufacturing
4
Non-energy minerals
1
Process industries
1
Professional, scientific, and technical services
2
Transportation and warehousing
1
Tags
Biopharma
52
Bioscience
39
Biotech
48
Biotech-bay
54
Biotech-beach
51
Biotechnology
49
Cancer
295
Cell
46
Children
40
Chmp
175
Clinical-trials-phase-ii
163
Clinical-trials-phase-iii
139
Conference
43
Covid
105
Covid-19
91
Disease
182
Drug
80
Europe
59
Events
47
Fda
105
Financial
46
Genetown
67
Global
64
Growth
110
Her2
50
Her2-
44
Liver
44
Market
95
Meeting
134
N/a
2349
Nasdaq
100
Ongoing
89
Pharm-country
75
Pharma
59
Pharmaceuticals
85
Phase 1
212
Phase 1b
49
Phase 2
273
Phase 2b
108
Phase 3
220
Positive
3049
Positive results
93
Potential
68
Pre-clinical
79
Preclinical
120
Presentation
47
Program
53
Report
59
Research
289
Results
883
Study
341
Technology
51
Test
57
Therapeutics
311
Therapy
186
Topline
359
Treatment
446
Trial
776
Update
50
Vaccine
105
Entities
4d pharma plc - adr
1
Abbvie inc.
1
Aclaris therapeutics, inc.
1
Adaptimmune therapeutics plc
1
Agios pharmaceuticals, inc.
1
Allogene therapeutics, inc.
2
Alnylam pharmaceuticals, inc.
2
Altimmune, inc.
1
Alzamend neuro inc
1
Amryt pharma plc
1
Aprea therapeutics, inc.
1
Aptevo therapeutics inc.
1
Atara biotherapeutics, inc.
1
Atossa therapeutics, inc.
1
Aveo pharmaceuticals, inc.
1
Axcella health inc.
1
Axsome therapeutics, inc.
2
Biogen inc.
1
Biolinerx ltd.
2
Capricor therapeutics, inc.
1
Cara therapeutics, inc.
1
Coherus biosciences, inc.
5
Compass pathways plc
1
Corcept therapeutics incorporated
2
Denali therapeutics inc.
1
Elanco animal health incorporated
1
Eli lilly and company
1
Evogene ltd.
2
Eyegate pharmaceuticals, inc.
2
Eyepoint pharmaceuticals, inc.
1
Galmed pharmaceuticals ltd.
1
Genfit s.a.
1
Glaxosmithkline plc
1
Global blood therapeutics, inc.
1
Hoth therapeutics, inc.
1
Humanigen, inc.
1
Immunic, inc.
1
Incyte corporation
1
Inventiva s.a.
1
Johnson & johnson
1
Kiniksa pharmaceuticals, ltd.
1
Landos biopharma inc
1
Longeveron llc - class a
1
Medicinova, inc.
1
Merit medical systems, inc.
1
Metacrine, inc.
1
Microbot medical inc.
1
Mirum pharmaceuticals, inc.
1
Morphic holding, inc.
1
Myovant sciences ltd.
1
Nanovibronix, inc.
1
Neogenomics, inc.
2
Novavax, inc.
1
Nrx pharmaceuticals inc
1
Palatin technologies, inc.
1
Pharmacyte biotech inc
2
Sanofi
3
Scynexis, inc.
3
Sorrento therapeutics, inc.
3
Tonix pharmaceuticals holding corp.
2
Symbols
ABBV
1
ACRS
1
ADAP
1
AGIO
1
ALLO
2
ALNY
2
ALT
1
ALZN
1
AMYT
1
APRE
1
APVO
1
ATOS
1
ATRA
1
AUY
1
AVEO
1
AXLA
1
AXSM
2
BIIB
1
BLRX
2
CAPR
1
CARA
1
CHRS
5
CMPS
1
CORT
2
DNLI
1
ELAN
1
EVGN
2
EYEG
2
EYPT
1
GBT
1
GLAXF
1
GLMD
1
GNFT
1
GSK
1
HGEN
1
HOTH
1
IMUX
1
INCY
1
IVA
1
JNJ
1
KNSA
1
LABP
1
LBPS
1
LGVN
1
LLY
1
MBOT
1
MIRM
1
MMSI
1
MNOV
1
MORF
1
MTCR
1
MYOV
1
NAOV
1
NEO
2
NRXP
1
PMCB
2
SCYX
3
SNY
3
SRNE
3
TNXP
2
Exchanges
Amex
1
Nasdaq
85
Nyse
9
Crawled Date
2022 - 03 - 15
2
2022 - 03 - 04
2
2022 - 02 - 11
3
2022 - 02 - 10
2
2022 - 01 - 04
2
2021 - 12 - 14
2
2021 - 12 - 13
2
2021 - 12 - 01
2
2021 - 09 - 21
1
2021 - 09 - 20
1
2021 - 09 - 17
1
2021 - 09 - 16
1
2021 - 09 - 13
1
2021 - 09 - 09
1
2021 - 09 - 02
1
2021 - 09 - 01
1
2021 - 08 - 16
1
2021 - 07 - 26
1
2021 - 07 - 23
1
2021 - 07 - 21
1
2021 - 07 - 19
1
2021 - 07 - 14
1
2021 - 07 - 06
1
2021 - 07 - 02
1
2021 - 06 - 23
1
2021 - 06 - 21
2
2021 - 06 - 11
1
2021 - 06 - 04
1
2021 - 06 - 03
1
2021 - 06 - 02
1
2021 - 06 - 01
2
2021 - 05 - 26
1
2021 - 05 - 24
1
2021 - 05 - 19
2
2021 - 05 - 17
1
2021 - 05 - 01
1
2021 - 04 - 20
1
2021 - 04 - 19
1
2021 - 04 - 16
1
2021 - 04 - 13
1
2021 - 04 - 12
1
2021 - 04 - 09
1
2021 - 03 - 25
1
2021 - 03 - 24
1
2021 - 03 - 17
1
2021 - 03 - 04
1
2021 - 03 - 02
1
2021 - 02 - 09
2
2021 - 02 - 02
1
2021 - 01 - 28
1
2021 - 01 - 14
1
2020 - 12 - 23
1
2020 - 12 - 21
2
2020 - 12 - 17
1
2020 - 12 - 16
1
2020 - 12 - 15
1
2020 - 12 - 08
1
2020 - 12 - 03
1
2020 - 12 - 02
1
2020 - 12 - 01
1
Crawled Time
00:00
2
01:00
1
06:00
2
07:00
1
08:00
3
09:00
1
11:00
3
11:01
1
11:02
1
12:00
9
12:01
3
12:04
1
12:15
3
12:30
4
12:58
2
13:00
11
13:15
2
13:30
3
14:00
10
14:15
2
15:00
6
15:30
1
15:56
1
16:00
2
16:20
1
17:00
1
19:00
3
20:00
3
21:00
6
22:00
3
22:15
1
Source
investor.aveooncology.com
1
ir.biolinerx.com
1
ir.hoththerapeutics.com
1
www.4dpharmaplc.com
1
www.biospace.com
43
www.globenewswire.com
40
www.inventivapharma.com
1
www.kindredbio.com
1
www.prnewswire.com
4
Sort by:
after hours % change
|
delayed % change
|
gain open
|
gain high
|
gain close
|
publishing date
(GMT-12:00) International Date Line West
(GMT-11:00) American Samoa
(GMT-11:00) Midway Island
(GMT-10:00) Hawaii
(GMT-09:00) Alaska
(GMT-08:00) Pacific Time (US & Canada)
(GMT-08:00) Tijuana
(GMT-07:00) Arizona
(GMT-07:00) Chihuahua
(GMT-07:00) Mazatlan
(GMT-07:00) Mountain Time (US & Canada)
(GMT-06:00) Central America
(GMT-06:00) Central Time (US & Canada)
(GMT-06:00) Guadalajara
(GMT-06:00) Mexico City
(GMT-06:00) Monterrey
(GMT-06:00) Saskatchewan
(GMT-05:00) Bogota
(GMT-05:00) Eastern Time (US & Canada)
(GMT-05:00) Indiana (East)
(GMT-05:00) Lima
(GMT-05:00) Quito
(GMT-04:00) Atlantic Time (Canada)
(GMT-04:00) Caracas
(GMT-04:00) Georgetown
(GMT-04:00) La Paz
(GMT-04:00) Puerto Rico
(GMT-04:00) Santiago
(GMT-03:30) Newfoundland
(GMT-03:00) Brasilia
(GMT-03:00) Buenos Aires
(GMT-03:00) Greenland
(GMT-03:00) Montevideo
(GMT-02:00) Mid-Atlantic
(GMT-01:00) Azores
(GMT-01:00) Cape Verde Is.
(GMT+00:00) Casablanca
(GMT+00:00) Dublin
(GMT+00:00) Edinburgh
(GMT+00:00) Lisbon
(GMT+00:00) London
(GMT+00:00) Monrovia
(GMT+00:00) UTC
(GMT+01:00) Amsterdam
(GMT+01:00) Belgrade
(GMT+01:00) Berlin
(GMT+01:00) Bern
(GMT+01:00) Bratislava
(GMT+01:00) Brussels
(GMT+01:00) Budapest
(GMT+01:00) Copenhagen
(GMT+01:00) Ljubljana
(GMT+01:00) Madrid
(GMT+01:00) Paris
(GMT+01:00) Prague
(GMT+01:00) Rome
(GMT+01:00) Sarajevo
(GMT+01:00) Skopje
(GMT+01:00) Stockholm
(GMT+01:00) Vienna
(GMT+01:00) Warsaw
(GMT+01:00) West Central Africa
(GMT+01:00) Zagreb
(GMT+01:00) Zurich
(GMT+02:00) Athens
(GMT+02:00) Bucharest
(GMT+02:00) Cairo
(GMT+02:00) Harare
(GMT+02:00) Helsinki
(GMT+02:00) Jerusalem
(GMT+02:00) Kaliningrad
(GMT+02:00) Kyiv
(GMT+02:00) Pretoria
(GMT+02:00) Riga
(GMT+02:00) Sofia
(GMT+02:00) Tallinn
(GMT+02:00) Vilnius
(GMT+03:00) Baghdad
(GMT+03:00) Istanbul
(GMT+03:00) Kuwait
(GMT+03:00) Minsk
(GMT+03:00) Moscow
(GMT+03:00) Nairobi
(GMT+03:00) Riyadh
(GMT+03:00) St. Petersburg
(GMT+03:30) Tehran
(GMT+04:00) Abu Dhabi
(GMT+04:00) Baku
(GMT+04:00) Muscat
(GMT+04:00) Samara
(GMT+04:00) Tbilisi
(GMT+04:00) Volgograd
(GMT+04:00) Yerevan
(GMT+04:30) Kabul
(GMT+05:00) Ekaterinburg
(GMT+05:00) Islamabad
(GMT+05:00) Karachi
(GMT+05:00) Tashkent
(GMT+05:30) Chennai
(GMT+05:30) Kolkata
(GMT+05:30) Mumbai
(GMT+05:30) New Delhi
(GMT+05:30) Sri Jayawardenepura
(GMT+05:45) Kathmandu
(GMT+06:00) Almaty
(GMT+06:00) Astana
(GMT+06:00) Dhaka
(GMT+06:00) Urumqi
(GMT+06:30) Rangoon
(GMT+07:00) Bangkok
(GMT+07:00) Hanoi
(GMT+07:00) Jakarta
(GMT+07:00) Krasnoyarsk
(GMT+07:00) Novosibirsk
(GMT+08:00) Beijing
(GMT+08:00) Chongqing
(GMT+08:00) Hong Kong
(GMT+08:00) Irkutsk
(GMT+08:00) Kuala Lumpur
(GMT+08:00) Perth
(GMT+08:00) Singapore
(GMT+08:00) Taipei
(GMT+08:00) Ulaanbaatar
(GMT+09:00) Osaka
(GMT+09:00) Sapporo
(GMT+09:00) Seoul
(GMT+09:00) Tokyo
(GMT+09:00) Yakutsk
(GMT+09:30) Adelaide
(GMT+09:30) Darwin
(GMT+10:00) Brisbane
(GMT+10:00) Canberra
(GMT+10:00) Guam
(GMT+10:00) Hobart
(GMT+10:00) Melbourne
(GMT+10:00) Port Moresby
(GMT+10:00) Sydney
(GMT+10:00) Vladivostok
(GMT+11:00) Magadan
(GMT+11:00) New Caledonia
(GMT+11:00) Solomon Is.
(GMT+11:00) Srednekolymsk
(GMT+12:00) Auckland
(GMT+12:00) Fiji
(GMT+12:00) Kamchatka
(GMT+12:00) Marshall Is.
(GMT+12:00) Wellington
(GMT+12:45) Chatham Is.
(GMT+13:00) Nuku'alofa
(GMT+13:00) Samoa
(GMT+13:00) Tokelau Is.
positive
tags :
Positive results
save search
Zai Lab Presents Positive Results from Phase 3 PRIME Study of ZEJULA® (Niraparib) at Society of Gynecologic Oncology Meeting
Published:
2022-03-21
(Crawled : 01:00)
- globenewswire.com
GLAXF
|
News
|
$19.54
-14.18%
2.6K
|
Health Technology
|
-4.03%
|
O:
4.8%
H:
4.09%
C:
4.09%
GSK
|
News
|
$40.86
-0.92%
-0.15%
1.7M
|
Health Technology
|
-3.42%
|
O:
0.96%
H:
0.0%
C:
0.0%
ZLAB
|
$15.66
3.57%
3.45%
430K
|
Health Technology
|
-56.95%
|
O:
10.34%
H:
0.0%
C:
0.0%
zejula
pos
positive results
positive
results
phase 3
primec
Lilly, BI-Partnered Kidney Trial Stopped Early Due to Positive Results
Published:
2022-03-16
(Crawled : 17:00)
- biospace.com/
LLY
|
News
|
$732.2
-1.81%
0.18%
2.1M
|
Health Technology
|
168.3%
|
O:
0.87%
H:
0.27%
C:
-0.51%
pos
kidney
trial
positive results
positive
results
Junshi Biosciences and Coherus Announce Presentation of Positive Results from CHOICE-01, a Phase 3 Clinical Trial Evaluating Toripalimab in Combination with Chemotherapy as First-Line Treatment for Non-Small Cell Lung Cancer, at March ASCO Plenary Series
Published:
2022-03-15
(Crawled : 13:30)
- globenewswire.com
CHRS
|
$2.03
-6.88%
-7.39%
720K
|
Health Technology
|
-81.92%
|
O:
1.41%
H:
5.81%
C:
2.53%
hoice-01
treatment
pos
trial
presentation
cel
positive results
asco
lung cancer
positive
therapy
bioscience
results
cancer
phase 3
Junshi Biosciences and Coherus Announce Presentation of Positive Results from CHOICE-01
Published:
2022-03-15
(Crawled : 12:30)
- biospace.com/
CHRS
|
$2.03
-6.88%
-7.39%
720K
|
Health Technology
|
-81.92%
|
O:
1.41%
H:
5.81%
C:
2.53%
hoice-01
pos
presentation
positive results
positive
bioscience
results
The Lancet Publishes Positive Results from Capricor Therapeutics’ Phase 2 Study Evaluating CAP-1002 in Late-Stage Duchenne Muscular Dystrophy
Published:
2022-03-11
(Crawled : 20:00)
- biospace.com/
CAPR
|
$5.04
4.56%
4.37%
910K
|
Health Technology
|
16.99%
|
O:
5.34%
H:
0.0%
C:
0.0%
cap-1002
phase 2
muscular dystrophy
pos
therapeutics
positive results
100
duchenne
positive
results
lancet
Coherus and Junshi Biosciences Announce Positive Results from Phase 3 Esophageal Cancer Study of Toripalimab Published in Cancer Cell
Published:
2022-03-04
(Crawled : 19:00)
- biospace.com/
CHRS
|
$2.03
-6.88%
-7.39%
720K
|
Health Technology
|
-81.14%
|
O:
-1.56%
H:
0.0%
C:
0.0%
pos
cel
positive results
positive
bioscience
results
cancer
phase 3
Junshi Biosciences and Coherus Announce Positive Results from Phase 3 Esophageal Cancer Study of Toripalimab Published in Cancer Cell
Published:
2022-03-04
(Crawled : 19:00)
- biospace.com/
CHRS
|
$2.03
-6.88%
-7.39%
720K
|
Health Technology
|
-81.14%
|
O:
-1.56%
H:
0.0%
C:
0.0%
pos
cel
positive results
positive
bioscience
results
cancer
phase 3
BioLineRx Announces Additional Positive Results from Pharmacoeconomic Study Comparing Motixafortide + G-CSF to Plerixafor + G-CSF in Stem Cell Mobilization
Published:
2022-03-03
(Crawled : 13:00)
- biospace.com/
BLRX
|
$0.5966
-6.31%
-6.74%
760K
|
Health Technology
|
-59.49%
|
O:
2.53%
H:
3.09%
C:
-3.09%
cel
positive results
stem cell
csf
positive
Skye Bioscience Reports Positive Results for SBI-100 in GLP Toxicology Study
Published:
2022-02-16
(Crawled : 14:00)
- biospace.com/
SKYE
|
$12.845
-8.45%
-9.23%
110K
|
Transportation and Warehousing
|
42159.04%
|
O:
-2.11%
H:
33.85%
C:
28.62%
sbi-100
positive results
100
report
positive
bioscience
results
NeoGenomics Liquid Biopsy Subsidiary Inivata and Collaborators Publish Positive Results from Prospective Clinical Study of RaDaR(TM) in Head and Neck Squamous Cell Carcinoma
Published:
2022-02-11
(Crawled : 08:00)
- biospace.com/
NEO
|
$14.03
-0.92%
-0.93%
540K
|
Health Services
|
-38.45%
|
O:
-1.5%
H:
0.0%
C:
0.0%
genomics
genomic
cel
positive results
positive
results
head and neck
cell carcinoma
Inivata and Collaborators Publish Positive Results from Prospective Clinical Study of RaDaR™ in Head and Neck Squamous Cell Carcinoma
Published:
2022-02-11
(Crawled : 08:00)
- biospace.com/
NEO
|
$14.03
-0.92%
-0.93%
540K
|
Health Services
|
-38.45%
|
O:
-1.5%
H:
0.0%
C:
0.0%
cel
positive results
positive
results
head and neck
cell carcinoma
Novavax Announces Positive Results of COVID-19 Vaccine in Pediatric Population of PREVENT-19 Phase 3 Clinical Trial
Published:
2022-02-10
(Crawled : 00:00)
- biospace.com/
NVAX
|
$4.15
-0.96%
-0.96%
2.4M
|
Health Technology
|
-95.44%
|
O:
-4.98%
H:
0.0%
C:
0.0%
covid-19
trial
covid
event-19
positive results
positive
vaccine
phase 3
SCYNEXIS Announces Positive Results from Its Pivotal Phase 3 CANDLE Study of Oral Ibrexafungerp for Prevention of Recurrent Vaginal Yeast Infections
Published:
2022-02-10
(Crawled : 13:00)
- biospace.com/
SCYX
|
$1.495
-3.55%
-3.68%
88K
|
Health Technology
|
-69.49%
|
O:
-3.54%
H:
7.45%
C:
4.29%
positive results
positive
infection
phase 3
infections
SCYNEXIS Announces Positive Results from Its Pivotal Phase 3 CANDLE Study of Oral Ibrexafungerp for Prevention of Recurrent Vaginal Yeast Infections, Clearing the Way for Regulatory Submission and Potential Approval of Additional Indication by End of 2022
Published:
2022-02-10
(Crawled : 13:00)
- globenewswire.com
SCYX
|
$1.495
-3.55%
-3.68%
88K
|
Health Technology
|
-69.49%
|
O:
-3.54%
H:
7.45%
C:
4.29%
approval
positive results
potential
positive
infection
phase 3
submission
infections
Hoth Therapeutics Announces HT-ALZ Therapeutic Shows Positive Results - Reduce Amyloid β in Alzheimer's Disease
Published:
2022-01-04
(Crawled : 13:00)
- ir.hoththerapeutics.com
HOTH
|
$1.19
1.2%
17K
|
Health Technology
|
68.89%
|
O:
61.79%
H:
53.51%
C:
14.04%
alzheimer
therapeutics
disease
positive results
positive
results
alzheimer’s
alzheimer's disease
alzheimer's
ht-alz
The Lancet Diabetes & Endocrinology Publishes Positive Results for the MPOWERED Phase 3 Trial for Mycapssa® (oral octreotide) in Acromegaly Patients
Published:
2022-01-04
(Crawled : 12:30)
- globenewswire.com
AMYT
|
News
|
$14.7
0.0%
2.4M
|
Health Technology
|
36.55%
|
O:
-1.3%
H:
0.0%
C:
0.0%
mycapssa
trial
diabetes
positive results
positive
results
phase 3
lancet
TRACON Pharmaceuticals Announces Positive Results from the Independent Data Monitoring Committee Review of Interim Safety and Efficacy Data from the Ongoing ENVASARC Pivotal Trial
Published:
2021-12-27
(Crawled : 14:00)
- globenewswire.com
TCON
|
$1.895
2.43%
2.37%
65K
|
Health Technology
|
-49.25%
|
O:
-9.47%
H:
0.0%
C:
-11.82%
als
ongoing
trial
positive results
positive
results
Immunic, Inc. Publishes Positive Results from the Single and Multiple Ascending Dose Parts of its Phase 1 Clinical Trial of IMU-935, a Potentially Best-in-Class Oral IL-17 Inhibitor
Published:
2021-12-14
(Crawled : 12:30)
- biospace.com/
IMUX
|
$1.24
0.0%
130K
|
Health Technology
|
-86.88%
|
O:
-3.49%
H:
1.75%
C:
-6.36%
imu-935
trial
positive results
phase 1
potential
positive
results
Atara Biotherapeutics Announces Positive Results from Pivotal Phase 3 Trial (ALLELE) of Tab-cel® at the 63rd American Society of Hematology (ASH) Annual Meeting
Published:
2021-12-14
(Crawled : 06:00)
- biospace.com/
ATRA
|
$0.7101
-1.18%
-1.2%
700K
|
Health Technology
|
-95.54%
|
O:
-4.53%
H:
4.22%
C:
2.01%
cel
ema
trial
therapeutics
positive results
tab-cel
positive
results
phase 3
iot
Allogene Therapeutics Reports Positive Results from Phase 1 UNIVERSAL Study of Single Dose ALLO-715 AlloCAR T™ Cell Therapy in Relapsed/Refractory Multiple Myeloma at the 63rd American Society of Hematology Annual Meeting
Published:
2021-12-13
(Crawled : 20:00)
- biospace.com/
ALLO
|
$3.04
-9.79%
-10.86%
2.1M
|
Health Technology
|
-81.31%
|
O:
1.05%
H:
2.52%
C:
-22.56%
allo-715
ema
therapeutics
positive results
phase 1
positive
therapy
results
t-cell
← Previous
1
2
3
4
5
Next →
Gainers vs Losers
62%
38%
Top 10 Gainers
CSSE
4
|
$0.4323
183.85%
64.77%
220M
|
Consumer Services
BOF
|
$1.99
70.09%
41.21%
110M
|
ILAG
|
$0.51
6.03%
40.62%
1.7M
|
LICN
|
$0.941
68.04%
40.49%
15M
|
AMST
|
$3.31
65.5%
39.58%
70M
|
Technology Services
MTC
|
$3.615
61.38%
38.04%
9.3M
|
Technology Services
WIMI
|
$1.15
58.53%
36.92%
19M
|
Technology Services
AIH
|
$0.45
12.5%
30.92%
320K
|
Health Services
MULN
|
News
|
$3.78
38.46%
27.78%
13M
|
Information
RILY
|
$29.86
37.48%
27.26%
12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.